CoChat
Sign Up
Cited by 308Diabetes Treatment and ManagementDiabetes Management and ResearchPancreatic function and diabetes

The DOI matches its Crossref record; 310 of the 310 references it cites were found in a registry or an index.

The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus

Rendell, Marc·2004·Drugs
DOI 10.2165/00003495-200464120-00006
Open this paper in CoChat — free account

Abstract

The sulphonylureas act by triggering insulin release from the pancreatic beta cell. A specific site on the adenosine triphosphate (ATP)-sensitive potassium channels is occupied by sulphonylureas leading to closure of the potassium channels and subsequent opening of calcium channels. This results in exocytosis of insulin. The meglitinides are not sulphonylureas but also occupy the sulphonylurea receptor unit coupled to the ATP-sensitive potassium channel. Glibenclamide (glyburide), gliclazide, glipizide and glimepiride are the primary sulphonylureas in current clinical use for type 2 diabetes mellitus. Glibenclamide has a higher frequency of hypoglycaemia than the other agents. With long-term use, there is a progressive decrease in the effectiveness of sulphonylureas. This loss of effect is the result of a reduction in insulin-producing capacity by the pancreatic beta cell and is also seen with other antihyperglycaemic agents. The major adverse effect of sulphonylureas is hypoglycaemia. There is a theoretical concern that sulphonylureas may affect cardiac potassium channels resulting in a diminished response to ischaemia. There are now many choices for initial therapy of type 2 diabetes in addition to sulphonylureas. Metformin and thiazolidinediones affect insulin sensitivity by independent mechanisms. Disaccharidase inhibitors reduce rapid carbohydrate absorption. No single agent appears capable of achieving target glucose levels in the majority of patients with type 2 diabetes. Combinations of agents are successful in lowering glycosylated haemoglobin levels more than with a single agent. Sulphonylureas are particularly beneficial when combined with agents such as metformin that decrease insulin resistance. Sulphonylureas can also be given with a basal insulin injection to provide enhanced endogenous insulin secretion after meals. Sulphonylureas will continue to be used both primarily and as part of combined therapy for most patients with type 2 diabetes.

Overview

Integrity signals

Registry

Crossref · 10.2165/00003495-200464120-00006

Cites

310 of 310 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 31

  1. Aguilar-Bryan, 1999, Endocr Rev, 20, 101
  2. Landstedt-Hallin, 1999, J Clin Endocrinol Metab, 84, 3140
  3. Prendergast, 1984, Clin Pharm, 3, 473
  4. Ylitalo, 1985, Arzneimittelforschung, 35, 1596
  5. Berger, 1985, Horm Metab Res Suppl, 15, 111
  6. Lao, 1994, Arzneimittelforschung, 44, 727
  7. El-Sayed, 1989, Int J Clin Pharmacol Ther Toxicol, 27, 551
  8. Ings, 1981, Br J Clin Pharmacol, 13, 264P
  9. Fujii, 1983, Arzneimittelforschung, 33, 1535
  10. Pentikainen, 1983, Int J Clin Pharmacol Ther Toxicol, 21, 98
  11. Kobayashi, 1988, Clin Pharm, 7, 224
  12. Ahren, 1986, Diabetes Res, 3, 293
  13. Ratheiser, 1993, Arzneimittelforschung, 43, 856
  14. Singh, 2002, J Assoc Physicians India, 50, 1232
  15. Carlson, 1993, Clin Ther, 15, 788
  16. Kilo, 1992, Clin Ther, 14, 801
  17. Cozma, 2002, J Clin Pharmacol, 42, 651, 10.1177/00970002042006007 · DOI
  18. Berger, 1986, Schweiz Med Wochenschr, 116, 145
  19. Sato, 2001, Arzneimittelforschung, 51, 459
  20. Rosenstock, 1996, Diabetes Care, 19, 1194, 10.2337/diacare.19.11.1194 · DOI
  21. Sami, 1996, J Fam Pract, 43, 370
  22. Ross, 2001, Clin Invest Med, 24, 292
  23. Olsson, 2002, Diabetes Metab, 28, 272
  24. Chan, 1998, Singapore Med J, 39, 186
  25. Lomuscio, 1994, Coron Artery Dis, 5, 767
  26. Hatorp, 1998, Int J Clin Pharmacol Ther, 36, 636
  27. Bakkali-Nadi, 1994, Diabetes Res, 27, 61
  28. Wolffenbuttel, 1993, Eur J Pharmacol, 45, 113
  29. Groop, 2000, Int J Clin Pract Suppl, 113, 3
  30. Johnston, 1998, J Clin Endocrinol Metab, 83, 1515
  31. Calle-Pascual, 1995, Diabete Metab, 21, 256

Cited by

Sorted by citations

See all 308

Related

See all

Metadata

Authors
Rendell, M.
Corresponding author
Rendell, Marc
ORCID
Rendell, Marc
Venue
Drugs
Publisher
Springer Science and Business Media LLC
Published
2004
Volume
64
Issue
12
Pages
1339-1358
ISSN
0012-6667 (ISSN-L)
DOI
10.2165/00003495-200464120-00006
OpenAlex
W2000845410
Cited by
308
References
310
Citations by year
2026: 5 · 2025: 7 · 2024: 7 · 2023: 9 · 2022: 5 · 2021: 11 · 2020: 9 · 2019: 10 · 2018: 16 · 2017: 13 · 2016: 19 · 2015: 17 · 2014: 19 · 2013: 21 · 2012: 22
FWCI
2.42
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
sulfonylureas, type 2 diabetes, insulin secretion, ATP-sensitive potassium channels, sulfonylurea receptor, glibenclamide, gliclazide, glipizide, glimepiride, hypoglycemia, meglitinides, metformin, thiazolidinediones, combination therapy, glycosylated haemoglobin, basal insulin, insulin resistance
MeSH terms
Benzamides, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Humans, Hypoglycemic Agents, Insulin, Sulfonylurea Compounds, Treatment Failure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review